Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K1-70 for active thyroid eye disease
2024-519292-26-00Phase 2Authorised
- Sponsor
- AV7 Ltd
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) and Graves' disease comparing K1-70 with Placebo to K1-70 (2 arms). Primary endpoint: Exophthalmos improvement rate at Week 24. Planned start May 2026; status: authorised.
02
Drugs
K1-70
03
Conditions
Graves Orbitopathy (GO)Graves' disease
Beyond the preview
Go deeper on 2024-519292-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519292-26-00.